Physician profile
Ashli Brooks
NPI 1417102146
$7,343.99
in general payments reported to CMS, 2019-2025
38 companies · $1,123 in 2025
The $1,123 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,705 · 2022: $1,799 · 2023: $1,695 · 2024: $1,022 · 2025: $1,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,750 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,749.76 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,710.90 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $692.94 | 2021-2025 | Minimed 780g, Inceptiv, Inpen Smart Insulin Delivery System |
| Lilly USA, LLC | $565.93 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $431.53 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $368.02 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $320.97 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $318.27 | 2021-2022 | |
| Amgen INC. | $295.77 | 2021-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $272.30 | 2021-2023 | Farxiga |
| Abbvie INC. | $246.02 | 2021-2025 | |
| Corcept Therapeutics | $244.00 | 2021-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $204.06 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Tandem Diabetes Care, INC. | $196.08 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.97 | 2022-2024 | Jardiance |
| Astellas Pharma US INC | $171.81 | 2023-2025 | Veozah |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $125.21 | 2021-2025 | Omnipod |
| Horizon Therapeutics Plc | $100.82 | 2022-2023 | Tepezza |
| Nevro Corp. | $96.73 | 2021 | |
| Abbott Laboratories | $84.41 | 2021-2025 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $83.63 | 2022-2024 | Unithroid |
| Novartis Pharmaceuticals Corporation | $80.86 | 2024-2025 | |
| Ultragenyx Pharmaceutical INC. | $77.57 | 2022 | |
| Ibsa Pharma INC. | $64.63 | 2022-2025 | Tirosint, Licart, Flector |
| Ascendis Pharma Endocrinology INC | $58.30 | 2025 | Yorvipath |
| Beta Bionics, INC. | $49.15 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amarin Pharma, INC. | $39.81 | 2021 | |
| Clarus Therapeutics INC. | $35.63 | 2021 | |
| Kyowa Kirin, INC. | $31.87 | 2023-2024 | Crysvita |
| Eton Pharmaceuticals, INC. | $24.84 | 2025 | Increlex, Alkindi, Khindivi |
| Eisai INC. | $24.18 | 2023 | |
| Blueprint Medicines Corporation | $21.78 | 2021 | |
| Pfizer INC. | $20.21 | 2023 | |
| Grt US Holding, INC. | $19.71 | 2022 | |
| Ascensia Diabetes Care US INC. | $19.28 | 2025 | |
| Recordati_rare_diseases_inc. | $18.77 | 2021 | |
| Opko Pharmaceuticals, LLC | $17.06 | 2021 | |
| Averitas Pharma INC. | $15.61 | 2023 | Qutenza |
| Tolmar Pharmaceuticals, INC. | $13.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashli Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.